drugset / Trial / NCT06553248

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes

NCT06553248

Phase 1 Completed 36 enrolled Gan and Lee Pharmaceuticals, USA
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in China. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of mutiple-dose GZR4 in subjects with type 2 diabetes

Timeline

Start
2023-03-22
Primary completion
2023-11-01
Completion
2023-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GZR4 Unknown Subcutaneous
Comparator insulin degludec Protein / enzyme biologic Subcutaneous